Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02718833 · ClinicalTrials.gov registry record · Phase 2

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 2
Development phase
52
Enrollment target
6
Study locations

NCT02718833: Active Phase 2 study of Multiple Myeloma, sponsored by Massachusetts General Hospital.

NCT02718833 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 52 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02718833, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
52 participants
Enrollment target
6
Study locations

Study Summary

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Pomalidomide
  • DRUG Bortezomib
  • DRUG Elotuzumab

Study Locations (6)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Dana-Farber Cancer Institute - Boston
  • Mass General/North Shore Cancer Center - Danvers
  • Newton-Wellesley Hospital - Newton

Michigan

  • University of Michigan - Ann Arbor

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2016-06-21
Est. Completion 2027-12
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02718833

The ClinicalTrials.gov registry entry for NCT02718833 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT02718833 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT02718833 about?

NCT02718833 is a clinical study titled "A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma". This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

What is the current status of trial NCT02718833?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2016-06-21. Estimated completion is 2027-12.

What conditions does trial NCT02718833 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02718833?

The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG), Elotuzumab (DRUG).

Who is sponsoring clinical trial NCT02718833?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02718833 being conducted?

This trial has 6 study locations across Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.